Pharmaceutical preparation for the therapy of immune deficiency conditions

- Cytoven J.V.

A pharmaceutical preparation for the therapy of immune deficiency conditions comprising an active principle--a peptide of the structure: H-L-Glu-L-Trp-OH and a pharmaceutically acceptable vehicle.

Skip to:  ·  Claims  ·  References Cited  · Patent History  ·  Patent History

Claims

1. A method for increasing the number of T-lymphocytes, B-lymphocytes or karyocytes in a non-human animal in need thereof comprising administering to the animal a pharmaceutical preparation comprising a pharmaceutically acceptable vehicle and a purified dipeptide having the amino acid sequence L-Glu-L-Trp, or a salt of said dipeptide, in an amount sufficient to cause said increase.

2. The method of claim 1 wherein the amount is 0.1.mu.g/kg to 1.mu.g/kg body mass of the animal.

3. The method of claim 1 wherein the amount is 1.mu.g/kg body mass of the animal.

4. The method of claim 1 wherein the animal suffers from radiation induced immune deficiency.

5. The method of claim 1 wherein the animal suffers from staphylococcal pyoderma.

6. The method of claim 1 wherein the animal suffers from a purulent-inflammatory disease of the bone or soft tissue, thyomegalia, thymectomy, rheumatoid arthritis or furunculosis.

7. The method of claim 1 wherein the animal suffers from an immune deficiency condition associated with cancer.

8. The method of claim 1 wherein the pharmaceutical composition is administered intramuscularly or intranasally.

9. The method of claim 1 wherein the pharmaceutical composition is administered intravenously.

10. The method of claim 1 wherein the amount of dipeptide or salt thereof is about 500.mu.g administered in several doses.

11. The method of claim 1 wherein the pharmaceutical preparation is administered in the form of an injectable solution.

12. The method of claim 1 wherein the pharmaceutical preparation is administered in the form of a tablet, a supporitorium, a capsule or an ointment.

13. The method of claim 1 wherein the pharmaceutically acceptable vehicle comprises an aqueous solution of sodium chloride, a novocain solution, distilled water, Ringer's solution or a solution of glucose.

14. The method of claim 1 wherein the pharmaceutically acceptable vehicle comprises starch, glucose or glycine.

Referenced Cited
U.S. Patent Documents
4428938 January 31, 1984 Kisfaludy et al.
4473554 September 25, 1984 Umezawa et al.
4699898 October 13, 1987 Gottlieb
4751216 June 14, 1988 Gottlieb
Foreign Patent Documents
0 240 033 October 1987 EPX
Other references
  • Declaration of John S. Sundsmo. N.S. Gee and A.J. Kenny (1987) Biochem. J. 246:97-102. Proteins of the kidney microvillar membranes. G. Belokrylov et al. (1986) Eksp. Biol. Medit. 102:51-53. Ability Of Some Amino Acids Incorporated Into Protein To Stimulate The Thymus-Dependent Immune Response. G. R. Pettit (1975) Synthetic Peptides, vol. 3, Academic Press, New York, New York, pp. 130, 134, 143, 424, 427, 429, 434. H. Sievertsson et al. (1971) Journal of Medicinal Chemistry, 15(1):8-11. Synthesis of Di-and Tripeptides and Assay in Vivo for Activity in the Thyrotrol Releasing Hormone and the Luteinizing Releasing Hormone Systems. Chem. Abstr. 116(17) 171986u (1990). Chem. Abstr. 111(17) 146389r (1989). Sandstrom et al. (1987) Drugs 34:372-390. Antiviral Therapy in AIDS Clinical Pharmacological Properties & Therapeutic Experience to Date. Remington's Pharmaceutical Sciences, 1980, pp. 996-997, 1465-1469, 1553-1557. Jaroff, Time May 23, 1988, pp. 56-64. Stop That Germ| ASM News vol. 56 1990, p. 368. Basmajian et al. (1982) Stedman's Medical Dictionary p. 1139.
Patent History
Patent number: 5674851
Type: Grant
Filed: Jun 7, 1995
Date of Patent: Oct 7, 1997
Assignee: Cytoven J.V. (Kirkland, WA)
Inventors: Vyacheslav G. Morozov (St. Petersburg), Vladimir K. Khavinson (St. Petersburg)
Primary Examiner: Paula K. Hutzell
Assistant Examiner: Benet Prickril
Application Number: 8/486,044
Classifications
Current U.S. Class: 514/19
International Classification: A61K 3805;